Nogid Anna, Pham David Q
Department of Pharmacy Practice, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, Brooklyn, New York 11201-5497, USA.
Pharmacotherapy. 2006 Nov;26(11):1626-40. doi: 10.1592/phco.26.11.1626.
Uncontrolled diabetes mellitus is associated with both microvascular and macrovascular complications. Despite an array of treatment options available, achievement of euglycemia in most patients with diabetes is still lacking. Pramlintide acetate, a synthetic analog of the human hormone amylin and belonging to a new class of agents, was approved in March 2005 as adjunctive treatment in patients with type 1 or 2 diabetes mellitus. To evaluate the data available on the efficacy and safety of pramlintide, we conducted a search of MEDLINE (January 1966-May 2006) and International Pharmaceutical Abstracts (January 1970-May 2006). Bibliographies of clinical trials were reviewed for additional references. The literature reviewed demonstrated that pramlintide is effective in reducing levels of glycosylated hemoglobin and potentially preventing weight gain. The most commonly reported adverse effects associated with pramlintide were nausea, anorexia, and hypoglycemia. These adverse effects occurred more often during the initiation of therapy and were usually mild to moderate in nature. Whether this therapy is a cost-effective option for patients with type 1 or type 2 diabetes mellitus is yet to be determined.
未控制的糖尿病与微血管和大血管并发症均相关。尽管有一系列可用的治疗选择，但大多数糖尿病患者仍难以实现血糖正常。醋酸普兰林肽是一种人类激素胰淀素的合成类似物，属于一类新型药物，于2005年3月被批准作为1型或2型糖尿病患者的辅助治疗药物。为评估有关普兰林肽疗效和安全性的现有数据，我们检索了MEDLINE（1966年1月至2006年5月）和国际药学文摘（1970年1月至2006年5月）。查阅了临床试验的参考文献以获取更多资料。所综述的文献表明，普兰林肽在降低糖化血红蛋白水平及可能预防体重增加方面有效。与普兰林肽相关的最常见不良反应是恶心、厌食和低血糖。这些不良反应在治疗开始时更常出现，且通常为轻至中度。这种治疗方法对1型或2型糖尿病患者是否具有成本效益尚待确定。
